Olema Pharmaceuticals, Inc. (OLMA)

12,36 -0,10 (-0,80%) Al cierre: 04:00PM EDT

Olema Pharmaceuticals, Inc.

780 Brannan Street
San Francisco, CA 94103
United States
415-651-3316
https://olema.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 75

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Sean P. Bohen M.D., Ph.D.	President, CEO & Director	1,15M	N/A	1967
Mr. Shane William Charles Kovacs M.B.A.	Chief Operating & Financial Officer	820,37k	N/A	1974
Dr. Naseem Zojwalla M.D.	Chief Medical Officer	753,37k	N/A	1973
Mr. Geoffrey Mogilner	Vice President of Investor Relations & Communications	N/A	N/A	N/A
Ms. Julie Dexter	Senior VP & Head of People	N/A	N/A	N/A
Dr. David C. Myles Ph.D.	Chief Discovery & Non-Clinical Development Officer	200k	N/A	1963
Ms. Demiana Faltaos Ph.D., Pharm.D.	VP & Head of Clinical Pharmacology	N/A	N/A	N/A
Mr. John B. Moriarty Jr., J.D.	Corporate Secretary	434,32k	N/A	1968
Ms. Sasha Austin CPA	VP of Finance & Controller	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de Olema Pharmaceuticals, Inc., a día 1 de junio de 2024, es 8. Las puntuaciones base son Auditoría: 6; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.